Health Science Reports (Apr 2024)

The impact of antibiotic resistance on the rampant spread of infectious diseases in Pakistan: Insights from a narrative review

  • Hania‐Tul Mirha,
  • Syed H. Ali,
  • Humna Aamar,
  • Mahnoor Sadiq,
  • Zoaib H. Tharwani,
  • Zehra Habib,
  • Abdullah Malikzai

DOI
https://doi.org/10.1002/hsr2.2050
Journal volume & issue
Vol. 7, no. 4
pp. n/a – n/a

Abstract

Read online

Abstract Background and Aims Antibiotic resistance (ABR) is a global public health emergency which has seen an uptick in low‐ to middle‐income countries in recent times due to a plethora of aggravating factors and has led to a whole host of setting‐specific pathogens registering high rates of resistance, causing outbreaks with graver mortality and morbidity. This review analyzes available literature to determine the causes and effects of ABR and recommend solutions to the problem in a Pakistani setting. Methods Sources for this narrative review were identified via electronic databases using keyword search methods. The information was retrieved using databases such as PubMed and Science Direct. Additionally, websites such as CDC and World Health Organization were used to attain pertinent information. All the sources were selected as per their relevance and appropriateness toward the purpose of this review. Results This review details the causes by dividing them into three primary strata, namely (1) under‐regulation, (2) over‐prescription and self‐medication, and (3) lack of medical stewardship. This is made much graver when the COVID‐19 pandemic and the subsequent erratic treatment response is considered, with the pandemic augmenting already high levels of consumption. These factors have led a cascade of effects including, but not limited to, a considerable increase in ABR in pathogens to first‐line drugs Conclusion ABR is a serious and growing issue which will result in undesirable personal, local, and national consequences if unchecked. Mitigation and reversal of this trend is necessary by developing existing programs and investing in novel therapies and pharmaceutical research and strengthening regulatory policies and mechanisms.

Keywords